Evaluation of a Method for Fibroblast Growth Factor-23: A Novel Biomarker of Adverse Outcomes in Patients with Renal Disease
- 1 December 2010
- journal article
- research article
- Published by Mary Ann Liebert Inc in Metabolic Syndrome and Related Disorders
- Vol. 8 (6), 477-482
- https://doi.org/10.1089/met.2010.0030
Abstract
Background: Fibroblast growth factor 23 (FGF-23), a phosphaturic peptide hormone secreted by the osteoblasts, is an important regulator of phosphorus and vitamin D metabolism. In chronic kidney disease, FGF-23 levels rise with declining kidney function. Increasing FGF-23 levels are associated with increasing risk of mortality in dialysis patients. Two assays for FGF-23 have been reported. One assay detects only full-length/intact FGF-23. In contrast, the carboxy-terminal assay recognizes both intact and carboxy-terminal FGF-23. Aim/Methods: The aim of this study was to evaluate both assays for FGF-23. Test samples were analyzed with both the intact and carboxy-terminal FGF-23 enzyme-linked immunosorbent assay (ELISA) kits according to manufacturers' instructions. Results: Carboxy-terminal FGF-23 showed very good precision with coefficients of variation (CV) ranging from 4% to 10.5%, whereas the CVs for intact FGF-23 were not very good (6–37.5%). The carboxy-terminal assay was linear, stable in plasma samples, and was not affected by common interferents. Also, the carboxy-terminal FGF-23 assay appeared to correlate better with worsening of kidney function as assessed by plasma creatinine and calculated estimated glomerular filtration rate (eGFR). Conclusion: Thus, the carboxy-terminal FGF-23 assay is robust and can be used in prospective trials to validate its utility as a biomarker of adverse outcomes in patients with renal disease.Keywords
This publication has 14 references indexed in Scilit:
- As nature did not predict dialysis--what we can learn from FGF23 in end-stage renal disease?Nephrology Dialysis Transplantation, 2009
- Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Comparison of two assays for fibroblast growth factor (FGF)-23Journal of Bone and Mineral Metabolism, 2005
- Structural and Biochemical Properties of Fibroblast Growth Factor 23Therapeutic Apheresis and Dialysis, 2005
- Role of fibroblast growth factor 23 in health and in chronic kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2005
- FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIaBiochemical and Biophysical Research Communications, 2004
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003
- Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemia in VivoEndocrinology, 2002